Nektar Therapeutics
NKTR
Updated: 23/09/2026, 06:04:49
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
No summaries found.
- Share price
- $60.97
- Market cap
- $1.75B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Howard W. Robin
- Employees
- 63
- IPO date
- 03/05/1994
- Beta
- 1.153
- Last dividend
- $0.00
- Day range
- $59.44 – $68.33
- 52-week range
- $33.40 – $109.00
- 1-day performance
- -8.78%
- 1-year performance
- 82.54%
- Current drawdown (1Y)
- -44.06%
- CIK
- 0000906709
- CUSIP
- 640268306
- ISIN
- US6402683063
- Created
- 07/12/2025, 05:27:27
- Last update
- 23/09/2026, 06:04:49
Track Nektar Therapeutics with an AI analyst
See which prediction-market events move NKTR, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Nektar Q1 Earnings & Revenues Lag Estimates, Pipeline in Focus
Zacks Investment Research • STOCK • 08/05/2026, 15:56:19
Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 08/05/2026, 07:11:18
Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
GlobeNewsWire • STOCK • 05/05/2026, 15:12:00
Bronstein, Gewirtz & Grossman LLC Urges Nektar Therapeutics Investors to Act: Class Action Filed Alleging Investor Harm
GlobeNewsWire • STOCK • 05/05/2026, 14:00:00
NKTR Deadline: NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit
PRNewsWire • STOCK • 04/05/2026, 23:54:00
NKTR DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
Newsfile Corp • STOCK • 04/05/2026, 23:22:00
NEKTAR THERAPEUTICS CLASS ACTION REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Nektar Therapeutics and Encourages Investors to Contact the Firm Before May 5th
GlobeNewsWire • STOCK • 04/05/2026, 20:57:00
NKTR INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026
Newsfile Corp • STOCK • 04/05/2026, 14:28:00
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR
PRNewsWire • STOCK • 04/05/2026, 06:02:00
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit with the Schall Law Firm
PRNewsWire • STOCK • 04/05/2026, 06:01:00
NKTR DEADLINE NOTICE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
Newsfile Corp • STOCK • 03/05/2026, 23:17:00
NKTR DEADLINE NOTICE: ROSEN, LEADING INVESTOR RIGHTS COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important May 5 Deadline in Securities Class Action - NKTR
Newsfile Corp • STOCK • 02/05/2026, 23:43:00